The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Grace Kong discussing the benefits ...

The first patient had extensive PSMA-avid disease at baseline and continued to demonstrate substantial disease on serial post ...

The Prostate Cancer Foundation framework summarizes five major components used for risk stratification: PSA level, tumor ...

The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Daniel Moon discussing the PRIMARY ...

She earned her MSN from Rush University Medical Center College of Nursing and holds advanced oncology nurse practitioner certification through the Oncology Nursing Certification Corporation. Brenda ...

Increasingly, 177 Lu-PSMA-617 is used for patients with mCRPC, while many of these patients may also require palliative ...

The 2026 ProsTIC annual meeting featured a Lutetium-177 session and a presentation by Dr. Renu Eapen discussing whether there ...

(UroToday.com) The 2026 ProsTIC annual meeting featured a PSMA imaging session and a presentation by Dr. Sidney Levy ...

Data from this study demonstrated progressive reductions in estimated glomerular filtration rate (eGFR) over time following initiation of 177 Lu-PSMA-I&T therapy, with trajectories shown separately ...

Quantitative PSMA uptake was the third prognostic biomarker highlighted, with increasing SUVmean associated with an HR of 1.74. Patients were stratified according to quartiles of SUVmean, with ...

The 2026 ProsTIC annual meeting featured a PSMA in Asia and Australia session and a presentation by Dr. Yao Zhu discussing PSMA imaging and theranostics in China today. Dr. Zhu organized his ...

Using baseline clinical data alone, the model incorporated prior treatments, blood-test results, ECOG performance status, PSA ...